New York State Teamsters Council Health & Hospital Fund

New York State Teamsters Council Health and Hospital Fund (commonly "NYS Teamsters Health & Hospital Fund"; the plan is sometimes styled "New York State Teamsters Council Health & Hospital Fund," Plan No. 501, EIN 15-0551885) is a Taft-Hartley multiemployer health and welfare trust headquartered at 151 Northern Concourse, Syracuse, New York. It was established in 1952 and is not a public company; it is an ERISA employee benefit plan governed by a board of trustees drawn equally from participating Teamsters locals and contributing employers. CauseIQ lists FY2024 revenue of roughly $222.7 million and total assets of about $854.7 million, with roughly 42–45 employees; the fund's own Summary Annual Report for 2023 reported $194.6 million in benefits paid to participants.

The fund is not a technology company and does not make or sell products. Its operations consist of administering collectively bargained benefits — hospital, medical, surgical, dental, vision, prescription drug, disability, death and legal services coverage — for eligible members of New York State Teamsters Council locals and their dependents, funded mainly by employer contributions (United Parcel Service being the largest single contributor).

Litigation posture: the fund is a plaintiff-only litigant in this database — 8 plaintiff cases, 0 defendant cases. It is neither an operating patent defendant nor a patent assertion entity; it holds no asserted patent portfolio. Rather, it sues as an end-payor purchaser of pharmaceuticals, and the eight tracked entries are duplicate docket records of a single June 18, 2020 complaint against Jazz Pharmaceuticals filed in the U.S. District Court for the Northern District of California.

All tracked cases were consolidated into In re Xyrem (Sodium Oxybate) Antitrust Litigation, MDL No. 20-md-02966 (N.D. Cal.), where the fund served as a putative class representative alongside the A.F. of L.–A.G.C. Building Trades Welfare Plan, the City of Providence, the Government Employees Health Association, Self-Insured Schools of California, UFCW Local 1500 Welfare Fund and a patient plaintiff. The suits alleged reverse-payment settlements delayed generic sodium oxybate competition. In April 2025 Jazz agreed to a $145 million settlement and Hikma a separate $50 million settlement, both subject to court approval; Jazz denied wrongdoing.